Vir Biotechnology and its CEO Marianne De Backer have notched yet another deal, this time with Gilead.
Gilead will pay Vir $65 million upfront, with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.